Status:
UNKNOWN
Treatment of Hepatitis c by Using Direct-acting Antiviral
Lead Sponsor:
Tanta University
Conditions:
Hepatitis C
Eligibility:
All Genders
18-75 years
Brief Summary
Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to dise...
Eligibility Criteria
Inclusion
- chronic hepatitis C patients had no other cause of liver disease
Exclusion
- Patients with hepatitis B virus (HBV).
- Patients with acute hepatitis.
- Patients with renal insufficiency.
- Patients with Hepatocellular carcinoma (HCC) or other types of malignancy.
- Patients on current use of melatonin.
- Patients using of any of medications that have interaction with melatonin.
- Patients work in night shifts.
- Patients are consuming a lot of caffeine or heavy smokers.
Key Trial Info
Start Date :
May 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05372874
Start Date
May 6 2022
End Date
July 30 2022
Last Update
May 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.